Clinical trial
A Phase Ⅰb/Ⅱ, Randomized, Double-blind, Placebo-controlled Study to Investigate the Tolerability, Safety,Pharmacokinetics and Efficacy of an Intravenous Treatment Regimen of GR1603 in Subjects with Systemic Lupus Erythematosus
NCT06015230 is registered in ClinicalTrials.gov with Genrix (Shanghai) Biopharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅰb/Ⅱ, Randomized, Double-blind, Placebo-controlled Study to Investigate the Tolerability, Safety,Pharmacokinetics and Efficacy of an Intravenous Treatment Regimen of GR1603 in Subjects with Systemic Lupus Erythematosus
- Lead sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- March 8, 2022
- Completion date
- October 4, 2028
- Enrollment
- 136 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.